Amgen Inc.

US$460.42As of Sun 8 Nov 2026, 12:00 UTC

NASDAQ:AMGNHealthcare

Country USA

PE (Fwd) •••

TSR 10Y CAGR 15.92%

Div yield 2.19%

ROE 78.35%

Drug Manufacturers (General)

Beta (5Y) 0.42

PE TTM 26.68

TSR TTM 58.56%

Mkt cap US$249.0B

ROIC 20.48%

SE Grade™

Value

Quality

Moat

Consensus

Reference

$505

9.61%

(63.79%)

Hold 2|6|10|5|8

TTM

FYE 31 Dec USD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

6.932

Revenue$B

27.98

28.14

28.42

29.03

29.88

29.99

29.54

30.25

30.99

30.47

7.214

0.39%

0.90%

24.97

Revenue growth%

19.07

18.55

18.28

21.21

18.33

19.53

17.72

20.64

23.46

25.77

15.28

20.64

19.30

29.07

Gross margin%

21.25

23.05

22.88

25.58

27.95

27.57

29.40

31.65

30.83

33.37

9.17

30.83

27.76

27.28

Operating margin%

25.16

26.53

27.82

26.69

28.73

30.51

28.37

25.59

27.47

25.34

14.32

27.47

27.08

8.63

Net margin%

0.40

2.21

3.42

0.62

0.40

0.53

3.38

5.60

8.55

29.19

3.38

1.42

23.10

P/E ratio (avg)x

10.85

11.36

12.32

11.57

10.35

9.337

8.801

7.943

8.152

8.307

33.01

8.307

9.845

10.15

EV/EBITx

30.44

32.52

31.98

37.93

37.48

42.23

44.09

44.58

47.93

54.58

37.17

44.58

40.08

21.72

FCF yield (avg)%

19.05

16.28

16.16

17.03

19.80

22.55

23.85

21.72

21.82

23.83

9.84

22.55

20.76

29.61

FCF margin%

0.76

1.38

2.00

3.67

2.14

0.40

1.78

0.40

2.03

18.97

0.40

1.58

1.455

FCF / Net incomex

1.282

1.172

1.248

1.077

1.119

1.170

1.216

1.298

1.357

1.257

0.142

1.257

1.232

6.00

ROIC%

17.51

17.97

15.29

18.16

18.50

15.88

13.82

16.80

16.36

17.97

7.44

16.36

17.16

8.15

Return on equity%

23.29

21.26

18.26

17.18

18.23

16.62

15.21

13.80

11.39

11.19

18.79

13.80

16.90

6.32

Return on assets%

23.50

25.42

22.76

23.93

21.14

19.62

19.86

21.22

23.30

22.44

19.68

21.22

22.60

50.15

EPS$

49.68

48.40

55.42

63.81

71.14

72.48

71.20

77.69

79.13

95.22

51.19

6.00%

7.43%

—

26.39

EPS growth%

9.30

8.09

7.03

6.91

8.30

6.62

5.08

7.56

4.62

3.91

27.04

5.08

6.97

76.85

Bookvalue per sh$

47.44

49.65

49.32

58.23

67.50

78.02

92.91

95.94

100.29

113.26

48.50

10.91%

10.98%

—

61.53

FCF per share$

54.34

58.26

63.82

66.26

64.18

58.54

60.01

60.71

56.32

57.53

29.23

(2.16%)

(0.13%)

—

24.19

Dividend per sh$

26.39

25.00

26.19

28.57

27.25

29.34

33.88

33.25

37.31

40.47

23.61

8.23%

4.88%

—

10.94

Div yield (avg)%

12.65

9.81

9.23

7.16

4.17

3.20

0.57

2.97

1.28

0.40

5.96

1.28

3.68

19.28

Payout ratio%

25.64

24.80

24.25

26.31

26.43

24.51

22.19

22.67

24.77

25.83

18.84

24.51

24.79

0.543

Shares (diluted)B

0.586

0.672

0.674

0.653

0.736

0.829

0.778

0.829

0.943

1.026

0.528

6.87%

5.77%

12.84

Buyback yield%

11.95

13.22

14.09

15.02

13.81

12.35

12.08

15.01

14.37

15.35

5.78

14.37

13.95

1.641

D/E ratiox

2.008

1.969

1.937

2.292

2.341

2.595

2.568

2.892

3.399

3.609

0.973

2.892

2.454

36.79

Enterprise value$B

42.91

43.55

43.50

46.25

52.40

52.14

56.66

65.05

71.32

80.56

35.37

8.98%

7.84%

19.45

LT debt$B

11.25

10.67

10.23

11.79

12.08

11.65

12.61

13.17

14.34

14.84

27.78

4.19%

3.36%

Peers (US$249.0B)

Cap (US$)

Merck & Co., Inc.

361.7B

148.4x

Gilead Sciences, Inc.

207.0B

—

Pfizer Inc.

167.5B

41.88x

AstraZeneca PLC

290.7B

26.20x

Capital

TTM

10Y

Leveragex

1.696

(0.180)

(0.196)

EBIT/Intx

1.812

0.072

0.101

Own earn%

389.16

(287.98)

(231.71)

Sh yield%

23.79

15.64

17.98

Owners

Insiders/Inst%

5.99

46.86

Short interest%

4.55

SBC / revenue%

3.22

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

25–31

$1 testx

−0.1

Incr. ROIC%

Amgen Inc. discovers, develops, manufactures and delivers human therapeutics worldwide, with principal products including Enbrel, Otezla, Prolia, Repatha, KYPROLIS and TEPEZZA for conditions such as psoriasis, osteoporosis, multiple myeloma and thyroid eye disease. It serves healthcare providers, including physicians, dialysis centers, hospitals and pharmacies, distributing through pharmaceutical wholesale distributors.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$30.47B

0.90%

1.00×

Cost of revenue

$14.40B

1.17%

1.03×

Operating expenses

$6.521B

0.57%

0.97×